Cardiac Dimensions develops minimally invasive treatments for heart failure and functional mitral regurgitation, with its flagship Carillon Mitral Contour System designed as a catheter-based therapy to restore natural mitral valve function. The Carillon device aims to reduce mitral regurgitation, improve quality of life, and has been associated in clinical studies with extended survival; it can be used as a front-line option and does not preclude future therapies. The company says the procedure promotes favorable left ventricular remodeling while avoiding damage to mitral valve leaflets. Cardiac Dimensions plans to use new financing to complete the EMPOWER Trial U.S. pivotal study and to continue commercialization and global commercial expansion of the Carillon therapy. The company recently closed an oversubscribed $53 million Series E financing led by Ally Bridge Group with significant participation from existing investors. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia; and Frankfurt, Germany. Cardiac Dimensions develops the Carillon Mitral Contour System, a minimally invasive, non-surgical device intended to restore mitral valve function and induce favorable left ventricular remodeling to reduce mitral regurgitation. The Carillon therapy is an indirect, no-touch annuloplasty designed to improve quality of life and extend survival and can be used alongside other heart-failure treatments. The device has obtained CE Mark and Therapeutic Goods Approval (TGA) and is approved for sale in Europe and Australia, while it is considered an investigational device in the U.S. To date, thousands of patients have been treated with the Carillon system worldwide, and positive safety and performance data encompassing more than 350 patients have been published from four studies and a real-world registry. Cardiac Dimensions is currently enrolling the U.S. EMPOWER pivotal trial and intends to use new financing to accelerate enrollment, broaden treatment to earlier-stage patients, and expand commercial sales in European markets with full reimbursement. The company has operations in Kirkland, Washington; Sydney, Australia; and Frankfurt, Germany. Cardiac Dimensions develops minimally invasive treatments for functional mitral regurgitation (FMR), centered on its Carillon Mitral Contour System®. The Carillon System uses a right-heart, transcatheter approach via the coronary sinus to reshape the mitral apparatus. The device is CE-marked (0344) and has been implanted in over 1,200 patients across the U.S., Europe, Australia, Turkey and the Middle East. The company is studying the device in the pivotal CARILLON Trial and it remains investigational in the United States. Management, led by CEO Rick Wypych, plans to accelerate commercial sales in Europe and expand into other geographies such as Australia. Recent regulatory progress includes approval from Australia’s Therapeutic Goods Administration for commercial use in FMR patients with mild to severe mitral regurgitation. The company closed a $17.5M Series C to support these commercial efforts. Cardiac Dimensions develops the Carillon Mitral Contour System, a minimally invasive, catheter-based device intended to treat functional mitral regurgitation by reducing the dilated mitral annulus. The company is building clinical evidence through multiple studies, including completing follow-up and publication of the randomized, double-blinded REDUCE FMR global study and continuing enrollment in The CARILLON U.S. pivotal trial. The Carillon System has CE Mark clearance and is available in certain European markets, including Turkey, the Netherlands and Italy. More than 850 patients worldwide have been treated with the device across completed international studies (AMADEUS, TITAN, TITAN II) and ongoing trials. Cardiac Dimensions intends to use new financing to support continued trial enrollment, complete the REDUCE FMR follow-up/publication, and expand its presence in global markets. The company has operations in Kirkland, Sydney and Frankfurt. Cardiac Dimensions develops minimally invasive treatment modalities for heart failure and related cardiovascular conditions, with an initial technology platform called the CARILLON Mitral Contour System designed to address functional mitral regurgitation via a percutaneous approach. The company is led by CEO Rick Stewart and is based in Kirkland, Washington; Sydney, Australia; and Frankfurt, Germany. It raised an additional $15.2M in this financing, bringing total capital raised to $43M. Proceeds are planned to fund the REDUCE FMR blinded, randomized clinical trial of a percutaneous mitral repair device in patients with functional mitral regurgitation. The company also intends to expand research and development projects and its commercial operations with the new funding.

Total raised

$188M

Funding rounds

8

Latest round

Series E

Latest activity

Mar 2025